Pyramid Analytics added to the DoD’s Tradewind Solutions Marketplace
8.6.2023 16:07:00 EEST | Business Wire | Press release
Pyramid Analytics (Pyramid), a leading business analytics and decision intelligence provider, is pleased to announce that its Pyramid Decision Intelligence Platform has been added to the Tradewind Solutions Marketplace, DoD’s digital environment of post-competition, readily awardable, technology solution pitch videos. The Tradewind Solutions Marketplace is the flagship offering of Tradewind, DoD’s suite of tools and services designed to accelerate the procurement and adoption of AI/ML, digital, and data analytics solutions across the DoD. Tradewind sits in the DoD’s Chief Digital Artificial Intelligence Office (CDAO).
The Pyramid Platform provides comprehensive, advanced analytics capabilities, including data pipelines and preparation (with embedded machine learning), enterprise and self-service data analytics, dashboarding (with built-in AI and chat-bots), and data science.
Pyramid’s platform was rated as “Awardable” and added to the Tradewind Solutions Marketplace. Solutions selected for the Marketplace, including the Pyramid Decision Intelligence Platform, have been assessed and vetted through competitive procedures, which satisfy the competition requirements of the Federal Acquisition Regulation (FAR), the Defense Federal Acquisition Regulation Supplement (DFARS), and the Statutes, Policies, and guidance applicable to the DoD’s Other Transaction Authorities.
Key points
- Pyramid’s platform is now listed on the Tradewind Solutions Marketplace, DoD’s digital platform for sourcing AI/ML, digital, and data analytics solutions.
- The DoD and the broader Defense Industrial Base has continued needs for low-code/no-code solutions that provide advanced analytics visualizations, machine learning, self-service analytics, natural language queries, and augmented and artificial intelligence.
- The Pyramid Platform received top ratings in leading analyst firm Gartner’s 2023 Critical Capabilities for Analytics and Business Intelligence Platforms report, including #1 for Business Analyst Use Case, #1 for Augmented Consumer Use Case, #2 for Data Scientist Use Case, and #4 for Analytics Developer Use Case.
- Pyramid’s US Federal Practice is led by a team of experienced leaders, including Joe Fritsch, Director of Federal Sales; Peter Morris, Senior Director of Partner Channel, North America; Dave Henry, Senior Vice President, Strategic Alliances; Russ Cosentino, Regional Vice President Sales, North America, East; and Brian McCormac, Senior Vice President of Global Sales.
“Being added to the Tradewind Solutions Marketplace is a significant recognition of the quality and relevance of our platform to the current and future needs of the defense industry. The Pyramid Decision Intelligence Platform offers comprehensive capabilities to support government agencies’ AI/ML, digital, and data analytics needs, enabling them to make faster and more informed decisions,” said Joe Fritsch, Director of Federal Sales at Pyramid Analytics.
In October 2022, Pyramid announced a new business practice dedicated to the US federal market, led by Joe Fritsch, and a strategic partnership with Carahsoft, The Trusted Government IT Solutions Provider®. This new DoD marketplace listing has strengthened its commitment to providing critical decision intelligence to government agencies.
The Pyramid Decision Intelligence Platform is already used by other government agencies, including the U.S. Department of Veterans Affairs, where it provides advanced analytics capabilities to over 50,000 users to help the VA manage, assess, and deliver quality healthcare to veterans across all VA hospitals.
Pyramid’s addition to the Tradewind Solutions Marketplace marks another significant milestone in the company’s dedication to helping U.S. federal civilian, defense, and intelligence agencies expand and optimize their use of data-informed decision intelligence at scale.
About Pyramid Analytics
Pyramid Analytics is the next generation of decision intelligence. The award-winning Pyramid Decision Intelligence Platform empowers people with augmented, automated, and collaborative insights that simplify and guide the use of data in decision-making. Critically, the Pyramid Platform operates directly on any data, enabling governed self-service for any person; and meeting analytical needs in a no-code environment without data extraction, ingestion, and duplication. It combines data prep, business analytics, and data science into one frictionless platform to empower anyone with intelligent decision-making. This enables a strategic, enterprise-wide approach to business intelligence and analytics, from the simple to the sophisticated. Schedule a demo today.
Pyramid Analytics USA is the U.S.-based subsidiary of Pyramid Analytics B.V. that is incorporated in Amsterdam with regional operations in global innovation and business centers, including New York City, London, and Tel Aviv. Our team lives worldwide because geography should not hinder talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital, and Viola Growth. Learn more at Pyramid Analytics.
For additional information on the Pyramid offerings in the Tradewind Solutions Marketplace, interested Government parties can log in at https://www.tradewindai.com/ and search for “Pyramid Analytics.” Registration is required.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230608005227/en/
Contact information
Pyramid Analytics
Pete Vomocil
SVP, Global Marketing, Pyramid Analytics
pr@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by market capitalization and is home to world-leading companies such as Samsung Electr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom